Mineralys Therapeutics, Inc. (MLYS) Stock Price, Chart & Analysis
About Mineralys Therapeutics, Inc. (MLYS)
Healthcare · Biotechnology
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NMS
- CEO
- Dr. Jon Congleton
- Employees
- 76
- IPO year
- 2023
- Market cap
- $1.6B
- EPS (TTM)
- $-4.22
- Book value
- $6.24
- 52-week range
- $18.11 – $47.65
- Beta
- 0.69
- Profit margin
- 0.0%
- Return on equity
- -80.9%